Tirzepatide associated with reduced type 2 diabetes and cardiovascular…
medicine Friday, August 23, 2024 Liverpool – With the dual GLP-1/GIP receptor agonist tirzepatide, patients not only lose more weight than with semaglutide. They also develop type 2 diabetes less frequently. And those with existing